↓ Skip to main content
What is this page? Embed badge

Small Molecules in Hematology

Overview of attention for book
Cover of 'Small Molecules in Hematology'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Imatinib Mesylate
  3. Altmetric Badge
    Chapter 2 Dasatinib
  4. Altmetric Badge
    Chapter 3 Nilotinib
  5. Altmetric Badge
    Chapter 4 Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor
  6. Altmetric Badge
    Chapter 5 Ponatinib: A Third-Generation Inhibitor for the Treatment of CML
  7. Altmetric Badge
    Chapter 6 Ruxolitinib
  8. Altmetric Badge
    Chapter 7 Ibrutinib
  9. Altmetric Badge
    Chapter 8 Pomalidomide
  10. Altmetric Badge
    Chapter 9 Enasidenib
  11. Altmetric Badge
    Chapter 10 Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytosis
  12. Altmetric Badge
    Chapter 11 Venetoclax: Targeting BCL2 in Hematological Cancers
  13. Altmetric Badge
    Chapter 12 Idelalisib
  14. Altmetric Badge
    Chapter 13 Carfilzomib
  15. Altmetric Badge
    Chapter 14 Acalabrutinib, A Second-Generation Bruton’s Tyrosine Kinase Inhibitor
Attention for Chapter 12: Idelalisib
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
62 Mendeley
Summary X Dimensions citations
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Idelalisib
Chapter number 12
Book title
Small Molecules in Hematology
Published in
Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer, January 2018
DOI 10.1007/978-3-319-91439-8_12
Pubmed ID
30069634
Book ISBNs
978-3-31-991438-1, 978-3-31-991439-8
Authors

Katja Zirlik, Hendrik Veelken, Zirlik, Katja, Veelken, Hendrik

Abstract

Idelalisib (GS-1101, CAL-101, Zydelig®) is an orally bioavailable, small-molecule inhibitor of the delta isoform (p110δ) of the enzyme phosphoinositide 3-kinase (PI3K). In contrast to the other PI3K isoforms, PI3Kδ is expressed selectively in hematopoietic cells. PI3Kδ signaling is active in many B-cell leukemias and lymphomas. By inhibiting the PI3Kδ protein, idelalisib blocks several cellular signaling pathways that maintain B-cell viability. Idelalisib is the first PI3K inhibitor approved by the US Food and Drug Administration (FDA). Treatment with idelalisib is indicated in relapsed/refractory chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and small lymphocytic lymphoma (SLL). This review presents the preclinical and clinical activity of idelalisib with a focus on clinical studies in CLL.

View on publisher site
X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
 Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 62 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 18%
Student > Ph. D. Student 9 15%
Student > Bachelor 7 11%
Student > Master 7 11%
Other 5 8%
Other 7 11%
Unknown 16 26%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 15 24%
Medicine and Dentistry 12 19%
Agricultural and Biological Sciences 6 10%
Pharmacology, Toxicology and Pharmaceutical Science 5 8%
Chemistry 4 6%
Other 4 6%
Unknown 16 26%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 August 2018.
All research outputs
#20,529,173
of 23,098,660 outputs
Outputs from Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer
#138
of 172 outputs
Outputs of similar age
#378,522
of 442,681 outputs
Outputs of similar age from Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer
#18
of 22 outputs
Altmetric has tracked 23,098,660 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 172 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 442,681 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.

This page is provided by Altmetric.